Wheatgrass

QUICK REF — Evidence: 2/5 (food-grade), 3/5 for two narrow adjunct uses | Dose: 30–60 mL fresh juice daily OR 3–5 g freeze-dried powder | Timing: morning, with or without food | Lab/Monitor: INR if on warfarin; HDL if using for lipids; CBC if using for thalassemia QOL | Key interactions: warfarin (vitamin K), hypoglycemics (theoretical), immunosuppressants (theoretical) | STATUS: CONDITIONAL — narrow niche uses (active distal UC adjunct, chemo myelotoxicity adjunct, acute dental pain) with very thin, unreplicated evidence. For general wellness, it is nutritionally equivalent to concentrated leafy greens — nothing more.

Wheatgrass is the juice or dried leaf powder of young Triticum aestivum shoots (7–10 days post-germination, harvested before grain formation). Marketed since the 1940s as a "superfood" on the back of Ann Wigmore's claims, it has one of the thinnest human evidence bases in the popular supplement category — roughly 7 controlled human trials across 25+ years, total cumulative human-N under 400. The most robust trial (Mutha 2018, PMID 29755902, N=69) was negative on its primary hematologic endpoint despite what the prior version of this file claimed. The second-most-cited trial (Ben-Arye 2002 UC, PMID 11989836) has not been replicated in 24 years. Safety is reassuring at oral doses (FAERS suspect-drug reports: 0), but mold/aflatoxin contamination of indoor-grown trays is a real theoretical risk with zero epidemiologic follow-up.

Clinical Summary

• What it is: Young wheat shoot (leaf stage, pre-grain) consumed as fresh juice, frozen juice, spray-dried or freeze-dried powder, or compressed tablets. Chlorophyll-rich (500–700 mg/100 g fresh); variable polyphenol content (apigenin, quercetin, caffeic acid, ellagic acid, catechin, coumarin, esculetin); non-heme iron, vitamin K, β-carotene, ascorbate in concentrated plant-food range.
• What the evidence actually shows: Signals for active distal UC symptom relief (1 RCT, N=23), breast-cancer chemotherapy myelotoxicity reduction (1 matched-control pilot, N=60), modest LDL lowering with concerning HDL drop (1 open-label RCT, N=59), and acute dental pulpitis pain relief at 30 minutes (1 RCT, N=45, 2026). Thalassemia transfusion-frequency reduction is contradicted by the largest randomized trial (Mutha 2018). Everything else — cancer, diabetes, liver disease, detox, immune-boosting, cognition, hair, skin — rests on animal, in vitro, or zero human data.
• What's folklore: "1 oz wheatgrass = 2.5 lb vegetables" (Schnabel 1942 marketing myth); "green blood / chlorophyll replaces hemoglobin" (porphyrin similarity misunderstood; chlorophyll is not absorbed intact); "P4D1 protein" (0 PubMed hits — Ann Wigmore-lineage lore, not biochemistry); cancer-cure and AIDS-cure claims (Ann Wigmore / Hippocrates Health Institute / Gerson lineage — documented patient deaths, cease-and-desist 2015).
• Who benefits from the hype: Juice bars ($3–5/oz), supplement brands (Amazing Grass, Organifi, Dr. Wheatgrass), Hippocrates Health Institute ($18k+ cancer-cure programs), Indian thalassemia-targeted vendors (despite the 2018 null RCT).
• Who it's actually suitable for: People who want a concentrated leafy-green supplement and accept it's roughly equivalent to kale/spinach on most nutrient axes; UC patients seeking an adjunct to standard therapy (with eyes-open on the 24-year lack of replication); people in active cancer chemotherapy whose oncologist has approved a myelotoxicity-adjunct attempt.

Indications & Evidence

Legend — Type codes: DC=Definitive Causal | PC=Probable Causal | UCC=Unreplicated Controlled Causal (one RCT/controlled study, no replication) | BC=Biomarker/Surrogate Causal | SE=Single Experiment | ME=Mechanistic Evidence only | AHE=Animal/Human Extrapolation | OA=Observational Association | RC=Replicated Case series | FA=Folk/Anecdotal | NE=No Evidence / debunked.

BH (Bradford Hill /9): strength, consistency, specificity, temporality, dose-response, plausibility, coherence, experiment, analogy. Scores ≥6/9 support causality; ≤3/9 means claim is unsupported.

Safety flags: -- = no FAERS signal identified / no data | MON = mild monitorable AEs (GI, nausea, headache) | WARN = serious FAERS signals related to indication pathway OR documented harm when replacing standard care | AVOID = contraindicated for that use.

Star ceilings by Type: DC 5/5 | PC 4/5 | UCC 3/5 | BC 3/5 | SE 3/5 | ME 2/5 | AHE 2/5 | OA 2/5 | RC 2/5 | FA 1/5 | NE 1/5.

Prescribing

Condition-Specific Protocols

These are the only indications with enough evidence to justify a protocol. All other "condition-specific" protocols in the prior version of this file were extrapolated from animal data or vendor marketing and have been removed.

Active distal ulcerative colitis (adjunctive)

• Dose: 100 mL fresh wheatgrass juice daily, morning, undiluted (Ben-Arye 2002 protocol)
• Duration: 1 month minimum; re-evaluate with treating gastroenterologist
• Position in therapy: ADJUNCT to 5-ASA / mesalamine / biologics. Do NOT discontinue standard therapy. Use only in remission or mild-moderate active disease; avoid during severe flare (fiber + raw juice risk).
• Monitor: Disease Activity Index, rectal bleeding frequency, CRP, fecal calprotectin. Reassess at 4 weeks; discontinue if no subjective benefit.
• Safety during immunosuppression: Raw juice in patients on biologics / corticosteroids carries infection risk (see Safety). Consider pasteurized or powder form.
• Evidence caveat: Single RCT from 2002, N=23, 21 completers, 19 analyzed. Never replicated in 24 years. This is the strongest wheatgrass indication by trial design — and it is still thin. PMID 11989836.

Breast cancer chemotherapy myelotoxicity (adjunctive — discuss with oncologist first)

• Dose: 60 mL fresh wheatgrass juice daily during chemotherapy cycles (Bar-Sela 2007 protocol)
• Duration: First three cycles of FAC regimen
• Position in therapy: ADJUNCT to supportive care. Does not replace G-CSF, epoetin, or dose-adjustment decisions. Discuss with oncologist — some oncologists avoid high-antioxidant interventions during cytotoxic chemo (theoretical concern about interference with reactive-oxygen-mediated tumor kill; not demonstrated clinically for wheatgrass).
• Monitor: CBC, ANC, hemoglobin, need for GCSF/epoetin support.
• Safety: Nausea worsened in 6/30 patients in the original trial, leading to cessation. Not suitable for severely immunosuppressed patients if using raw juice (contamination risk).
• Evidence caveat: Matched-control prospective pilot, not randomized. N=60. Never replicated in 18+ years. PMID 17571966.

Acute dental pulpitis pain (sublingual)

• Dose: 500 mg wheatgrass extract sublingually for acute pain (Sabah 2026 protocol)
• Duration: Single acute dose; no multi-dose or long-term data
• Position in therapy: Emerging; not a substitute for definitive endodontic treatment. May be adjunct when NSAIDs contraindicated.
• Evidence caveat: One RCT, N=45, 30-min endpoint only, single-center India. PMID 41636988.

Safety

Adverse Effect Profile

FAERS Signal Table (OpenFDA, accessed 2026-04-17)

Interpretation: There is no FAERS signal against wheatgrass itself. This matches the known pattern where FAERS data on food-grade supplements consists almost entirely of concomitant-use noise from other drugs in affected populations.

Contraindications (Absolute)

• Celiac disease unless product is certified gluten-free by third-party testing. Wheatgrass leaves (pre-grain) do not synthesize mature gluten proteins, but seed / husk cross-contamination during processing is a documented risk and has not been quantified in published celiac safety studies.
• Wheat or grass allergy (IgE-mediated). Anaphylaxis has been reported (rare).
• Severe immunocompromise (AIDS, post-transplant, ANC <500) if using raw juice — infection risk from E. coli, Salmonella, Listeria.

Contraindications (Relative)

• Pregnancy and lactation: Insufficient safety data; raw juice carries Listeria risk.
• Pediatric use <12 yr outside supervised thalassemia protocols.
• Within 2 weeks of surgery: Theoretical warfarin-antagonism via vitamin K.
• Severe CKD (GFR <30) or dialysis: Potassium content ~180–250 mg / 100 g fresh.
• History of kidney stones: Oxalate content not well-characterized; precautionary.

Drug Interactions

Special Populations

• Elderly: Lower adult dose (15–30 mL juice or 1–2 g powder); more interaction risk from polypharmacy; GI tolerance may be lower.
• Renal impairment (moderate, GFR 30–59): Halve dose; monitor K⁺ and phosphorus quarterly.
• Renal impairment (severe, GFR <30 / dialysis): Avoid — potassium load.
• Hepatic impairment Child-Pugh C: No human data — use cautiously if at all.
• Pregnancy / lactation: Avoid raw juice products due to Listeria risk; no data on safety of powder products; no excretion data in milk.
• Pediatric: Only supervised use in thalassemia-protocol context (Mutha 2018).
• Active cancer on chemotherapy: Only with oncologist approval; matches the published protocol (60 mL WGJ fresh during FAC).
• Severely immunocompromised: Use powder or pasteurized product — raw juice is not safe.

Contamination & Quality Concerns (underappreciated)

• Mold / aflatoxin risk: Wheatgrass is commonly grown hydroponically in trays at room temperature for 7–10 days — a classic Aspergillus / Fusarium niche. White mold is routinely visible on poor-quality home-grown trays. No regulator has published mycotoxin limits specific to wheatgrass juice. This is the single most under-covered safety issue in the popular literature. Commercial products from reputable brands test for mycotoxins, but home-grown and juice-bar products often do not.
• Bacterial contamination: E. coli, Salmonella, Shigella, Listeria — all documented risks of raw juice products. FDA has repeatedly flagged raw juice as high-risk. Pasteurization or powder form reduces risk substantially.
• Gluten cross-contamination: See celiac contraindication above.
• Cultivar variability: Flavonoid content varies >5-fold across wheat cultivars (PMID 39199145). Batch-to-batch potency is effectively uncontrolled; there is no USP or equivalent standardization.
• Zinc / iron bioavailability is overstated: A 2025 human dual-isotope cross-over RCT (PMID 41231541, N=36) showed that sprouting wheat did not significantly increase fractional zinc absorption — challenging a common marketing claim.

Synergies & Stacking

Antagonistic / Competitive Interactions

• High-dose Calcium (supplemental or dairy): Competes with iron absorption via DMT1. Space by 2–3 hours if using wheatgrass for iron.
• Coffee / Tea tannins: Modestly reduce iron absorption; space by 1 hour if iron-optimization is a goal.
• Phytate-rich meals: Reduce mineral bioavailability — minor concern.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Nothing else has been studied. Zero data on FUT2 secretor status, APOE, VDR, chlorophyllin-metabolizing UGTs/GSTs, or P-glycoprotein variants with wheatgrass.

Community & Anecdotal Evidence

DISCLAIMER: Everything in this section is anecdotal, community-sourced, or marketing. It is NOT clinical evidence. It is included to map the user landscape and identify manipulation patterns, not to support efficacy claims.

Source Communities

Folk-Dosing vs Clinical Dosing

Commonly Reported Subjective Effects (Folk vs Evidence)

Red Flags & Skepticism Notes

• Ann Wigmore / Hippocrates Health Institute legacy — CRITICAL RED FLAG. Ann Wigmore had no accredited medical credentials (per National Council Against Healthcare Fraud). HHI co-directors Brian and Anna-Maria Clement received cease-and-desist orders for unlicensed practice of medicine in 2015. The Makayla Sault case (Canadian child pulled from McMaster Children's Hospital leukemia treatment, sent to HHI for wheatgrass + enemas + raw food at $18,000, died) is the most infamous documented harm.
• Gerson Therapy — CRITICAL RED FLAG. Wheatgrass-juice + coffee-enema cancer regimen. NCI: no evidence of efficacy. Documented deaths from hyponatremic coma, sepsis, electrolyte imbalance. Closely related Gonzalez therapy: pancreatic cancer patients on chemo survived 3× longer than those on Gonzalez regimen.
• "1 oz wheatgrass = 2.5 lb vegetables" — marketing myth traced to Charles Schnabel's 1942 letter. The original claim was "15 lb wheatgrass = 350 lb vegetables"; scaled down to the familiar meme. Nutrient analyses do not support any such ratio. Repeated uncritically by every wheatgrass vendor for 80+ years.
• "Chlorophyll = green blood" — oversimplification. Porphyrin ring similarity is real (Mg-centered in chlorophyll, Fe-centered in heme). Functional equivalence is not — chlorophyll is NOT absorbed intact and is degraded to pheophytin in the stomach. No human evidence of hemoglobin-building from ingested chlorophyll.
• "P4D1 protein" — folklore, not biochemistry. Zero PubMed hits for "P4D1 wheatgrass." Repeated in Ann Wigmore-lineage literature as if it were an identified molecular entity. It is not.
• Indian thalassemia-targeted vendor marketing — aggressive despite the 2018 Mutha RCT's null primary endpoint. Ethically questionable.
• Mercola vendor framing ("highly detoxifying medicinal herb, should not be used long-term") — contradicts daily-use community and conveniently serves product-cycle economics.
• Dr. Wheatgrass Australia, 800wheatgrass.com testimonial farms — uncontactable testimonials, excessive emotional language, SEO-optimized affiliate content.
• Drew Canole / Organifi — direct-to-consumer (not MLM), but textbook influencer affiliate playbook. Wheatgrass is one of many ingredients in "Green Juice."
• No major MLM brand found — this was explicitly checked. Unlike Herbalife / doTERRA / Young Living, wheatgrass hasn't spawned a pyramid ecosystem. It is retail + affiliate + e-commerce.
• Japanese aojiru legitimacy borrowing — aojiru is primarily barley grass or kale (invented Oct 1943 by Dr. Niro Endo for wartime nutrition; commercialized 1983 by Q'SAI); Western wheatgrass marketing uses "aojiru" imagery loosely.
• Indoor-grown mold risk — community-surfaced issue that gets little vendor acknowledgement.

Folk vs Clinical Reality Check

The most telling signal in the community map is not what people claim wheatgrass does, but the narrow range of claims that overlap with clinical evidence. Community UC reports match Ben-Arye 2002 qualitatively. Community "energy" and "morning clarity" claims have no clinical counterpart — they are classic greens-powder placebo territory. Community cancer-cure claims exist only in a documented-harm subculture (Wigmore / HHI / Gerson). The 1940s–1980s Charles Schnabel / Ann Wigmore marketing legacy continues to drive more of today's public wheatgrass narrative than the published trials do.

Deep Dive

What Actually Is Wheatgrass

Young vegetative Triticum aestivum (common wheat) harvested at 7–10 days post-germination, 15–20 cm in height, before grain formation. Juiced fresh (classic presentation), flash-frozen, spray-dried at ~80–120 °C, or freeze-dried at low temperature. Compressed tablets and capsules are second-generation forms. Chlorophyll a and b dominate the pigment profile; polyphenol load (apigenin, quercetin, kaempferol, luteolin, ferulic / caffeic / p-coumaric acids, catechin, ellagic acid, coumarin, esculetin) varies >5× across cultivars (PMID 39199145). Vitamin K1 content is high enough to matter for warfarin patients. Non-heme iron content is meaningful but absorption is phytate-constrained.

The Evidence Base — What Actually Exists

Seven controlled human trials across 24 years, total cumulative N under 400:

1. Ben-Arye et al. 2002 (PMID 11989836) — Double-blind placebo-controlled RCT in active distal UC. N=23 (19 analyzed). 100 mL WGJ daily × 1 month. Significant reduction in Disease Activity Index (p=0.031) and rectal bleeding (p=0.025). No serious side effects. Never replicated in 24 years. This is the strongest wheatgrass indication by trial design and is still structurally weak.

2. Marwaha et al. 2004 (PMID 15297687) — Non-randomized pilot in beta-thalassemia major, N=16. Each patient served as own historical control (1 year prior transfusion data). 100 mL WGJ daily. 50% had >25% reduction in transfusion requirement; 3/16 had >40% reduction. This is the source of the oft-cited "40% transfusion reduction" claim — which comes from a pilot, not an RCT.

3. Bar-Sela et al. 2007 (PMID 17571966) — Prospective matched-control (not randomized) pilot in breast-cancer patients on FAC chemotherapy. N=60, 60 mL WGJ daily during first 3 cycles. Censoring events (premature termination, dose reduction, G-CSF / epoetin initiation) 5 vs 15 (p=0.01). Chemo response rate not diminished. Nausea worsened in 6/30 WG arm. Never replicated in 18+ years.

4. Kumar & Iyer 2017 (PMID 28121470) — RCT (no placebo, no blinding) in post-menopausal South Asian hyperlipidemic women, N=59. 3.5 g freeze-dried WG powder daily × 10 weeks. TC −5.4%, LDL −4.4%, TAG −9.5% — and HDL −6% (adverse). Menopausal-symptom scores non-significant. HDL drop under-discussed in secondary citations.

5. Mutha et al. 2018 (PMID 29755902) — Prospective randomized open-label trial in thalassemic children on chronic transfusion, N=69 enrolled (57 completed). 100 mg/kg/day × 18 months. NO difference in transfusion frequency or volume between groups — the primary hematologic endpoint was null. Liver size reduced in WG group (p<0.021) at 18 months; spleen-size reduction significant in both arms; ferritin unchanged. QOL improved (p<0.05). Conclusion stated cautiously as "promising role." This is the most rigorous thalassemia trial and it contradicts the Marwaha 2004 pilot. The prior version of this file incorrectly attributed a 40% transfusion-volume reduction to this trial; this has been corrected.

6. Avisar et al. 2020 (PMID 32585974) — Patient-preference-allocation (not randomized) controlled cohort in Stage II–III colon cancer on adjuvant chemo, N=100. 60 mL WGJ daily × 5–6 months. IL-10 rose significantly; IL-6 / IL-8 / IL-12 unchanged. No tumor-response or survival data. Self-selection bias. A substudy (PMID 32984039) added extracellular-vesicle biomarker data with lower endothelial-EV counts in WG arm.

7. Sabah et al. 2026 (PMID 41636988) — RCT, N=45, adults with irreversible pulpitis. Sublingual WG extract 500 mg vs piroxicam 20 mg vs placebo. Pain reduction (NPRS 0–10) at 30 minutes: WG > piroxicam > placebo (both active arms p < 0.05 vs placebo; WG significantly better than piroxicam). Single-center India. 30-minute endpoint only. CTRI/2024/12/078719.

ClinicalTrials.gov

Active / Recruiting: 0. Completed with posted results: 0.

Mechanism — What Holds Up in 2026

• Polyphenol / flavonoid antioxidant profile — apigenin, quercetin, catechin, caffeic acid, ellagic acid, coumarin, esculetin. Bioavailability variable; most flavonoids undergo Phase II glucuronidation / sulfation. Established in vitro; translation to clinical benefit not demonstrated.
• Chlorophyll — 70% of dry phytochemical mass in some preparations. Degraded to pheophytin in stomach acid. Not absorbed intact. The "oxygen-carrying plant-blood" narrative is mechanistically wrong.
• Maltoheptaose — TLR-2 monocyte activation (PMID 23629653) — the first actually-well-defined molecular immunomodulator from wheatgrass. Induces CD69, IL-12, TNF-α in monocytes. Hypothesis-generating only.
• Wheatgrass polysaccharide WGP — NF-κB suppression, MAPK inhibition in LPS-liver injury model (PMID 28543910). Preclinical.
• HIF-1α / EMT suppression in A549 airway epithelium (PMID 28386380) — Korean work; hypothesis for chronic rhinosinusitis. Preclinical.
• ERK/Akt–CREB–BDNF neuroprotection + tau-phosphorylation attenuation in mouse scopolamine amnesia (PMID 35861716). Preclinical.
• BPA endocrine protection in rat uterus/ovary via apigenin-mediated TNF-α inhibition, BCL2↑, p53/BAX normalization (PMID 39600302). Preclinical.

Mechanism — What Doesn't Hold Up

• P4D1 "protein" — not a recognized biochemical entity in PubMed. Ann Wigmore-era brand lore.
• Chlorophyll-as-blood-substitute — oversimplified porphyrin-ring analogy. Chlorophyll not absorbed intact.
• "Wheat germ agglutinin" as a relevant concern — WGA is concentrated in the grain kernel, not the young grass harvested pre-grain.
• "Alkalization" — blood pH is tightly regulated (7.35–7.45) by respiratory and renal systems. Diet does not change blood pH. Urine pH changes are excretion, not "body pH."
• "Detoxification" — no valid clinical mechanism; the liver and kidneys continuously detoxify. No human study shows wheatgrass increases toxin excretion.

Ataraxia Verdict

as of 2026-04-17

Hype Check

The evidence-to-hype ratio for wheatgrass is one of the worst in the popular supplement landscape. The Ben-Arye 2002 UC RCT and the Bar-Sela 2007 chemo pilot — both small, both Israeli, both from the same institutional cluster — have been weaponized by marketers as "clinical proof" for 20+ years despite never being replicated. The Charles Schnabel 1942 "1 oz = 2.5 lb vegetables" myth persists unchallenged in nearly every vendor's copy. The Ann Wigmore / Hippocrates Health Institute lineage has directly contributed to documented patient deaths by steering people away from standard cancer care. Despite this, community sentiment is only softly positive — the biohacker subreddits do not treat wheatgrass as a darling. That disconnect is itself diagnostic: the loudest wheatgrass promotion comes from commercial actors, not from users converting on outcome.

Evidence Classification

️ Evidence Gaps

• Zero dedicated wheatgrass meta-analyses. Too few trials.
• Zero 2020+ systematic reviews focused on wheatgrass.
• Zero replication of the two canonical positive trials (Ben-Arye UC, Bar-Sela chemo) in 18–24 years.
• Zero pharmacogenomic data — no sex-stratified, no genotype-stratified, no FUT2, no MTHFR, no APOE studies.
• Zero longevity / telomere / aging-biomarker human data.
• Zero gut microbiome human studies.
• Zero epidemiologic follow-up on mold / aflatoxin contamination despite the obvious risk of indoor-grown trays.
• Zero clinical pharmacokinetics. No ADME study of chlorophyll, polyphenols, or any other WG component as administered from whole wheatgrass.
• Cultivar / batch variability >5× in flavonoid content (PMID 39199145) means "dose" is operationally meaningless without per-batch standardization.

Bias Flags

• Single-region evidence cluster: Indian (Mumbai, Pune, Mumbai, Rajasthan) and Israeli (Haifa, Carmel) groups dominate the human trial literature. Replication by independent Western labs is absent. This does not invalidate the findings but amplifies concerns about methodological consistency and publication-selection.
• Small-trial publication bias: Most trials are N<70, open-label, single-center. The kinds of trials that systematically over-estimate effect sizes.
• Outcome-reframing bias in the popular literature: Mutha 2018's null primary endpoint is often cited as if it were positive, because QOL (a secondary outcome) improved. The prior version of this file did exactly that — it attributed a 40% transfusion-volume reduction to Mutha 2018 when that number actually came from Marwaha 2004's non-randomized pilot. This is a pattern, not an isolated slip.
• Ayurvedic / holistic framing bias: The Indian research community has a strong traditional-medicine prior for wheatgrass benefit. This is legitimate but worth flagging.

Manipulation Flags

• Ann Wigmore / Hippocrates Health Institute cult-adjacent marketing — critical. Documented cease-and-desist (2015). Documented patient deaths. The HHI "Life Transformation Program" still charges $18,000+ for wheatgrass-centric cancer-adjacent regimens.
• Gerson Therapy ecosystem — critical. Wheatgrass-juice + coffee-enema cancer protocol. NCI: no evidence. Deaths documented.
• Schnabel 1942 "1 oz = 2.5 lb vegetables" myth propagated uncritically by every major vendor for 80+ years.
• Cultic Wigmore-descendant claims — "P4D1 protein," "energy enzyme soup," "oxygenates blood" — cited as if molecular fact.
• Indian thalassemia family-targeted marketing despite Mutha 2018 null RCT.
• Mercola self-serving framing ("medicinal herb, not a food, don't use long-term") — drives product-cycle economics.
• Dr. Wheatgrass Australia, 800wheatgrass.com, drewcanole.com affiliate / testimonial farms — classic patterns (uncontactable testimonials, emotional language, SEO optimization, affiliate disclosure buried).
• 10-angle red-team: logical consistency (alkalization claim contradicts physiology; "enzyme therapy" contradicts digestion); cui bono (juice bars, HHI, Gerson, supplement brands, Indian vendors — all benefit from hype; no major actor benefits from fear, which matches the reassuring FAERS picture); time-horizon (80+ years of marketing produced 7 controlled trials — that ratio alone is damning); steelman (leafy-green nutrient concentration is real; narrow UC / chemo / dental signals are non-zero); reversibility (no long-term harm documented at oral doses); second-order effects (displacement of real cancer treatment is the catastrophic tail risk); historical precedent (Laetrile, Gerson, Essiac — similar marketing arcs); emotional loading ("green blood," "nature's medicine") is heavy; stranger test (would a stranger looking at 7 trials call this "proven"? No.); analogical reasoning (wheatgrass → leafy greens is defensible; wheatgrass → pharmaceutical is not).

Decision Support

• Health utility score: 4 / 10 — compound-intrinsic. Food-grade with a few narrow niches. Penalized for the evidence-to-hype ratio, zero replication of canonical trials, cultivar-variability problem, and red-flag lineage.
• Opportunity cost: Juice bars run $600–2,000/year; powder is $100–360/year. Time cost for juicing is high. Taste cost is real (dose-limiting nausea). Cognitive cost of managing warfarin / diabetes med interactions.
• Hell Yes or No (Sivers): No for general wellness. Conditional yes for: (1) active distal UC patients already on standard therapy, as an adjunct, for 1 month trial; (2) breast-cancer patients on FAC chemo who discuss with oncologist; (3) people curious about the sublingual acute-pain use for dental emergencies. No for everything else.
• Regret minimization: In 5 years, if the Ben-Arye UC trial finally gets replicated (or definitively refuted) and Mutha 2018's null result gets cited as strongly as its positive ancillary outcomes, would you regret not having tried wheatgrass? Probably not. Would you regret having it documented accurately in your vault with the evidence-inflation caught? Yes — that's the value of this file.
• Verdict: CONDITIONAL. Narrow justified niches; not a general-wellness staple. For general antioxidant / green-food goals, whole leafy vegetables (spinach, kale, parsley) are equally or more effective, better characterized, and cheaper.

Bottom Line

Wheatgrass is a nutritionally concentrated leafy plant with two or three narrow, unreplicated controlled-trial signals (active distal UC, breast-cancer chemo adjunct, acute dental pain), a contradicted thalassemia claim, and a long history of dangerous fringe-medicine association that has gotten people killed. Oral safety at food-grade doses is reassuring. Batch-to-batch variability is severe. For most people, kale is equivalent and honest.

Practical Notes

Brands & Quality Markers

Quality markers to look for: USDA Organic; Non-GMO Project Verified; GMP certified; third-party mycotoxin testing (the most important and the most commonly omitted); heavy-metal testing (lead, cadmium, arsenic, mercury); microbial testing (E. coli, Salmonella, yeast, mold); chlorophyll content listed ≥2,500 mg / 100 g for powders.

Storage

• Fresh juice: consume within 30 minutes of juicing; refrigerated ≤24 hours; oxidation rapid
• Frozen juice: −18 °C / 0 °F; 6–12 months
• Powders: cool dry place; 12–24 months unopened; refrigerate after opening to extend; 6–12 months after opening
• Tablets / capsules: room temperature 15–25 °C; avoid humidity; 18–24 months

Palatability

• Taste: intensely grassy, earthy, slightly sweet; many find it unpalatable especially as juice
• Masking: pineapple / mango juice; ginger; lemon (also boosts iron absorption via vitamin C); cold temperature
• Shot method: 1–2 oz consumed quickly then chase with preferred beverage
• Start low (1–2 g powder or 15 mL juice) to build tolerance

Exercise & Circadian

• Post-workout: Theoretical antioxidant-for-recovery framing, no specific data. High-dose antioxidants may blunt exercise adaptations (established for vitamin C + E; not tested for wheatgrass specifically).
• Pre-workout: Not recommended — fiber / GI irritation risk.
• Morning: Traditional timing; no pharmacokinetic basis, matches cultural practice and avoids before-bed GI sensitivity.

Reference Ranges to Monitor

• INR (if on warfarin): maintain consistent daily WG intake or avoid
• HDL (if using for lipids): Kumar 2017 showed adverse HDL drop; re-check at 10 weeks
• CBC + transfusion frequency (if thalassemia context): Mutha 2018 did NOT show transfusion-frequency benefit — expect null on primary; potential QOL / liver-size benefit at 18 months
• Blood glucose (if on insulin / sulfonylurea): monitor first 2 weeks for additive hypoglycemia
• Potassium (if CKD): do not use at GFR <30

Cost

What We Don't Know

• Whether Ben-Arye 2002's UC signal replicates — it is 24 years old and no one has tried.
• Whether Bar-Sela 2007's chemo myelotoxicity signal replicates — a phase III trial was called for in 2007 and has never been done.
• Whether Mutha 2018's QOL / liver-size signal in thalassemia is real or an open-label artifact.
• Whether the 2026 Sabah dental-pulpitis finding holds beyond 30 minutes or single-center conditions.
• The actual bioavailability of any wheatgrass constituent in humans (zero ADME studies).
• Whether indoor-grown wheatgrass mold / aflatoxin contamination contributes to some of the reported "detox reactions" — no epidemiologic data.
• Whether seed / husk gluten cross-contamination matters clinically in celiac patients — no dedicated safety study.
• Whether any sex, HLA, MTHFR, or other genetic modifier changes response — zero studies.
• Whether product standardization (chlorophyll content, flavonoid profile) would move any of the effect sizes — no standardized-extract trial exists.
• Whether the IL-10 signal in Avisar 2020 translates into any clinical benefit.
• Why the HDL drop in Kumar 2017 happened and whether it generalizes.

References

Human controlled trials

1. Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E (2002). Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 37(4):444–9. PMID: 11989836. RCT N=23, 100 mL WGJ/d × 1 month, DAI ↓ p=0.031.
2. Marwaha RK, Bansal D, Kaur S, Trehan A (2004). Wheat grass juice reduces transfusion requirement in patients with thalassemia major: a pilot study. Indian Pediatr 41(7):716–20. PMID: 15297687. Non-randomized pilot N=16, 50% reduced transfusion ≥25%.
3. Bar-Sela G, Tsalic M, Fried G, Goldberg H (2007). Wheat grass juice may improve hematological toxicity related to chemotherapy in breast cancer patients: a pilot study. Nutr Cancer 58(1):43–8. PMID: 17571966. Matched-control prospective pilot N=60, censoring events 5 vs 15 (p=0.01).
4. Kumar N, Iyer U (2017). Impact of Wheatgrass on Atherogenic Lipoproteins and Menopausal Symptoms in Hyperlipidemic South Asian Women — A Randomized Controlled Study. J Diet Suppl 14(5):503–13. PMID: 28121470. Open-label RCT N=59, TC/LDL/TAG ↓, HDL −6%.
5. Mutha AS, Shah KU, Kinikar AA, Ghongane BB (2018). Efficacy and Safety of Wheat Grass in Thalassemic Children on Regular Blood Transfusion. Cureus 10(3):e2306. PMID: 29755902. Prospective randomized N=69, no difference in transfusion frequency or volume; liver size ↓ p<0.021 at 18 mo; QOL ↑ p<0.05.
6. Avisar A, Cohen M, Katz R, et al. (2020). Wheatgrass Juice Administration and Immune Measures during Adjuvant Chemotherapy in Colon Cancer Patients: Preliminary Results. Pharmaceuticals (Basel) 13(6):129. PMID: 32585974. Patient-preference cohort N=100, IL-10 ↑.
7. Avisar A, Cohen M, Aharon A, Aharoni-Simon M, Katz R, Bentur OS, Brenner B, Bar-Sela G (2020). Extracellular Vesicles Reflect the Efficacy of Wheatgrass Juice Supplement in Colon Cancer Patients During Adjuvant Chemotherapy. Front Oncol 10:1659. PMID: 32984039. EV biomarker substudy.
8. Sabah S, Shobana K, Mitthra S, Madhubala MM, Venkatesh KV (2026). Evaluation of the analgesic effect of sublingual administration of wheatgrass extract for dental pain management in irreversible pulpitis. Odontology [Epub Feb 4 2026]. PMID: 41636988. RCT N=45, sublingual 500 mg WG > piroxicam > placebo at 30 min.

Systematic reviews / narrative reviews

9. Langhorst J, Wulfert H, Lauche R, et al. (2015). Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis 9(1):86–106. PMID: 25518050. Wheatgrass mentioned as investigational CAM; evidence too weak to recommend.
10. Bar-Sela G, Cohen M, Ben-Arye E, Epelbaum R (2015). The Medical Use of Wheatgrass: Review of the Gap Between Basic and Clinical Applications. Mini Rev Med Chem 15(12):1002–10. PMID: 26156538. The definitive "gap" review; calls for RCTs that never came.
11. van den Driessche JJ, Plat J, Mensink RP (2018). Effects of superfoods on risk factors of metabolic syndrome: a systematic review of human intervention trials. Food Funct 9(4):1944–66. PMID: 29557436. Wheatgrass: 1 usable trial (Kumar 2017), insufficient to conclude.
12. Tamraz M, Al Ghossaini N, Temraz S (2024). The Role of Wheatgrass in Colorectal Cancer: A Review of the Current Evidence. Int J Mol Sci 25(10):5166. PMID: 38791211. "Minimally investigated and evidence is still limited."
13. Bangera D, Sikalgar FR, Shetty PP, et al. (2025). Therapeutic Potential of Wheatgrass Juice: A Comprehensive Narrative Review. J Pharm Bioallied Sci 17(Suppl 1):S152–4. PMID: 40511096. Narrative, concedes weak evidence.

Mechanistic / phytochemical

14. Parit SB, Dawkar VV, Tanpure RS, et al. (2018). Nutritional Quality and Antioxidant Activity of Wheatgrass (Triticum aestivum) Unwrap by Proteome Profiling and DPPH and FRAP assays. J Food Sci 83(8):2127–39. PMID: 30059150. 297 proteins identified; antioxidant activity quantified.
15. Gunjal M, Kaur J, Rasane P, et al. (2024). Nutritional Significance of Wheatgrass: Cultivation Practices and Opportunities for its Processing and Preservation. Recent Adv Food Nutr Agric 15(3):163–77. PMID: 38305314. Flags aflatoxin/mycotoxin risk.
16. Karabıyıklı Ş, Doğan K (2026). Wheatgrass juice powder phenolics dock against ER, EGFR, IKKβ, CXCR4, SOD, CAT, Keap1 in silico; cytotoxic to MCF-7. PMID: 41588140. In vitro only.
17. Chen et al. (2024). Flavonoid content varies >5× across 145 wheat cultivars. PMID: 39199145. Critical product-variability paper.
18. Korean group (2024). Purple Arriheuk wheat sprout extract inhibits dexamethasone-induced muscle atrophy via Akt/mTOR + AMPK/Foxo3 in mice and C2C12 cells. PMID: 39388119.
19. Narula et al. (2024). Methanolic WG extract protects rat uterus / ovary against BPA-induced inflammation via apigenin and catechin. PMID: 39600302.
20. Korean group (2017). Wheatgrass suppresses hypoxia-induced EMT + mucin hypersecretion in A549 (HIF-1α pathway). PMID: 28386380 (see also 28216876).
21. Taiwan/UK collab (2024–2025). Taiwanese green propolis + wheatgrass + mulberry compound + daylight PDT for glioblastoma / RCC. PMID: 40725143 (see also 39925210).
22. Durairaj V, Shakya G, Rajagopalan R (2015). Hepatoprotective Role of Wheatgrass on Alcohol and deltaPUFA-Induced Oxidative Stress in Rats. J Diet Suppl 12(2):126–37. PMID: 24697162.
23. Lim JY, Yun DH, Lee JH, et al. (2021). Extract of Triticum aestivum Sprouts Suppresses Acetaminophen-Induced Hepatotoxicity in Mice. Molecules 26(21):6336. PMID: 34770745.
24. Shakya G, Randhi PK, Pajaniradje S, et al. (2016). Hypoglycaemic role of wheatgrass in type II diabetic rats. Toxicol Ind Health 32(6):1026–32. PMID: 25116122.
25. Adhikary M, Mukhopadhyay K, Sarkar B (2021). Flavonoid-rich wheatgrass diet attenuates diabetes by modulating antioxidant genes in STZ-induced diabetic rats. J Food Biochem 45(4):e13643. PMID: 33547672.
26. Gore RD, Palaskar SJ, Bartake AR (2017). Wheatgrass: Green Blood can Help to Fight Cancer. J Clin Diagn Res 11(6):ZC40–ZC42. PMID: 28764290. In vitro only.

Bioavailability / zinc-iron

27. Belgian human cross-over N=36, dual-isotope Zn absorption study (2025). Sprouting wheat did NOT significantly increase fractional Zn absorption. PMID: 41231541. Challenges the high-bioavailability narrative.

Cosmetic safety

28. Cosmetic Ingredient Review Expert Panel (2025). 21 of 27 wheat-derived cosmetic ingredients assessed as safe; 6 with insufficient data. PMID: 39517108. Topical cosmetics only — does NOT apply to oral wheatgrass.

Stability / product quality

29. Qamar A, Saeed F, Nadeem MT, et al. (2019). Probing the storage stability and sensorial characteristics of wheat and barley grasses juice. Food Sci Nutr 7(2):554–62. PMID: 30847134.

Retractions / Corrections

• PMID 38213153 (Recent Patents on Nanotechnology 2024) — "Wheatgrass extract loaded chitosan solid lipid nanoparticles: formulation..." — WITHDRAWN. Flagged here so the retraction is not accidentally re-cited.

External reference points

• Examine.com: No dedicated wheatgrass entry as of 2026-04-17.
• NIH Office of Dietary Supplements: No fact sheet.
• FDA GRAS Notice Inventory: No explicit wheatgrass GRAS Notice — sold as a dietary ingredient under DSHEA.
• EFSA Novel Food Catalogue: Not listed (considered pre-1997 food with history of consumption in EU).
• Australia TGA: Listed under AUST L (low-risk complementary medicine ingredient); no approved therapeutic claims.
• Quackwatch (Stephen Barrett): Wheatgrass therapy critique — classic skeptic reference.
• NCI PDQ: Gerson therapy — "No scientific evidence for efficacy."
• ClinicalTrials.gov active trials for wheatgrass: 0 recruiting; 2 registered total (NCT01215448 completed 2013 without posted results; NCT05851040 unknown status since 2023-10).